Peter Andersen

List of Publications by Year in Descending Order

323 papers	22,533 citations	80 h-index	136 g-index
330 ext. papers	25,406 ext. citations	7.1 avg, IF	6.67 L-index

#	Paper	IF	Citations
323	Monocytes Elicit a Neutrophil-Independent Th1/Th17 Response Upon Immunization With a Mincle-Dependent Glycolipid Adjuvant.. *Frontiers in Immunology*, **2022**, 13, 880474	8.4	0
322	A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin. *Nature Communications*, **2021**, 12, 6658	17.4	1
321	A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars. *Npj Vaccines*, **2021**, 6, 58	9.5	3
320	Antigen Expression Regulates CD4 T Cell Differentiation and Vaccine Efficacy against Mycobacterium tuberculosis Infection. *MBio*, **2021**, 12,	7.8	2
319	antigen expression regulates CD4 T cell differentiation and vaccine efficacy against infection **2021**,		1
318	Chitin-derived polymer deacetylation regulates mitochondrial reactive oxygen species dependent cGAS-STING and NLRP3 inflammasome activation. *Biomaterials*, **2021**, 275, 120961	15.6	4
317	Intrapulmonary (i.pulmon.) Pull Immunization With the Tuberculosis Subunit Vaccine Candidate H56/CAF01 After Intramuscular (i.m.) Priming Elicits a Distinct Innate Myeloid Response and Activation of Antigen-Presenting Cells Than i.m. or i.pulmon. Prime Immunization Alone. *Frontiers in Immunology*, **2020**, 11, 603	8.4	8
316	CD4 T cell proliferative responses to PPD and CFP-10 associate with recent M. tuberculosis infection. *Tuberculosis*, **2020**, 123, 101959	2.6	1
315	Parenteral vaccination protects against transcervical infection with and generate tissue-resident T cells post-challenge. *Npj Vaccines*, **2020**, 5, 7	9.5	15
314	Type I IFN signalling is required for cationic adjuvant formulation (CAF)01-induced cellular immunity and mucosal priming. *Vaccine*, **2020**, 38, 635-643	4.1	1
313	Vaccine Adjuvants Differentially Affect Kinetics of Antibody and Germinal Center Responses. *Frontiers in Immunology*, **2020**, 11, 579761	8.4	9
312	Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines. *Communications Biology*, **2020**, 3, 563	6.7	10
311	Rescuing ESAT-6 Specific CD4 T Cells From Terminal Differentiation Is Critical for Long-Term Control of Murine Mtb Infection. *Frontiers in Immunology*, **2020**, 11, 585359	8.4	7
310	Diagnostic Accuracy of Interferon Gamma-Induced Protein 10 mRNA Release Assay for Tuberculosis. *Journal of Clinical Microbiology*, **2020**, 58,	9.7	6
309	Immunization with -Specific Antigens Bypasses T Cell Differentiation from Prior Bacillus Calmette-Guérin Vaccination and Improves Protection in Mice. *Journal of Immunology*, **2020**, 205, 2146-2153	5.3	9
308	Metabolic Profiling and Compound-Class Identification Reveal Alterations in Serum Triglyceride Levels in Mice Immunized with Human Vaccine Adjuvant Alum. *Journal of Proteome Research*, **2020**, 19, 269-278	5.6	2
307	Design of Gadoteridol-Loaded Cationic Liposomal Adjuvant CAF01 for MRI of Lung Deposition of Intrapulmonary Administered Particles. *Molecular Pharmaceutics*, **2019**, 16, 4725-4737	5.6	4

306	HCV p7 as a novel vaccine-target inducing multifunctional CD4 and CD8 T-cells targeting liver cells expressing the viral antigen. *Scientific Reports*, **2019**, 9, 14085	4.9	11
305	Diagnostic Accuracy of Early Secretory Antigenic Target-6-Free Interferon-gamma Release Assay Compared to QuantiFERON-TB Gold In-tube. *Clinical Infectious Diseases*, **2019**, 69, 1724-1730	11.6	7
304	Parenteral Vaccination With a Tuberculosis Subunit Vaccine in Presence of Retinoic Acid Provides Early but Transient Protection to Infection. *Frontiers in Immunology*, **2019**, 10, 934	8.4	7
303	Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques. *Npj Vaccines*, **2019**, 4, 21	9.5	27
302	Moving tuberculosis vaccines from theory to practice. *Nature Reviews Immunology*, **2019**, 19, 550-562	36.5	63
301	Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 140, 29-39	5.7	16
300	Genital Infiltrations of CD4 and CD8 T Lymphocytes, IgA and IgG Plasma Cells and Intra-Mucosal Lymphoid Follicles Associate With Protection Against Genital Infection in Minipigs Intramuscularly Immunized With UV-Inactivated Bacteria Adjuvanted With CAF01. *Frontiers in Microbiology*, **2019**, 10, 197	5.7	6
299	Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 220-231	10.2	43
298	Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate infection in aerosol-challenged mice. *Communications Biology*, **2019**, 2, 288	6.7	17
297	Site-Specific DC Surface Signatures Influence CD4 T Cell Co-stimulation and Lung-Homing. *Frontiers in Immunology*, **2019**, 10, 1650	8.4	6
296	Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. *Lancet Infectious Diseases, The*, **2019**, 19, 1091-1100	25.5	48
295	Maternal Antibodies Inhibit Neonatal and Infant Responses to Vaccination by Shaping the Early-Life B Cell Repertoire within Germinal Centers. *Cell Reports*, **2019**, 28, 1773-1784.e5	10.6	28
294	Mucosal boosting of H56:CAF01 immunization promotes lung-localized T cells and an accelerated pulmonary response to Mycobacterium tuberculosis infection without enhancing vaccine protection. *Mucosal Immunology*, **2019**, 12, 816-826	9.2	24
293	A Liposome-Based Adjuvant Containing Two Delivery Systems with the Ability to Induce Mucosal Immunoglobulin A Following a Parenteral Immunization. *ACS Nano*, **2019**, 13, 1116-1126	16.7	12
292	IL-33 Is a Negative Regulator of Vaccine-Induced Antigen-Specific Cellular Immunity. *Journal of Immunology*, **2019**, 202, 1145-1152	5.3	1
291	Unusual Self-Assembly of the Recombinant Chlamydia trachomatis Major Outer Membrane Protein-Based Fusion Antigen CTH522 Into Protein Nanoparticles. *Journal of Pharmaceutical Sciences*, **2018**, 107, 1690-1700	3.9	2
290	T Cells Primed by Live Mycobacteria Versus a Tuberculosis Subunit Vaccine Exhibit Distinct Functional Properties. *EBioMedicine*, **2018**, 27, 27-39	8.8	23
289	Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder. *Vaccine*, **2018**, 36, 3331-3339	4.1	19

288	Targeting the Mincle and TLR3 receptor using the dual agonist cationic adjuvant formulation 9 (CAF09) induces humoral and polyfunctional memory T cell responses in calves. *PLoS ONE*, **2018**, 13, e0201253	3.7	12
287	Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System. *Frontiers in Immunology*, **2018**, 9, 380	8.4	12
286	Overcoming the Neonatal Limitations of Inducing Germinal Centers through Liposome-Based Adjuvants Including C-Type Lectin Agonists Trehalose Dibehenate or Curdlan. *Frontiers in Immunology*, **2018**, 9, 381	8.4	22
285	Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C). *Frontiers in Immunology*, **2018**, 9, 898	8.4	8
284	Transcriptomics of the Vaccine Immune Response: Priming With Adjuvant Modulates Recall Innate Responses After Boosting. *Frontiers in Immunology*, **2018**, 9, 1248	8.4	18
283	Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. *New England Journal of Medicine*, **2018**, 379, 138-149	59.2	327
282	A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522. *Journal of Controlled Release*, **2018**, 271, 88-97	11.7	35
281	Immunocorrelates of CAF family adjuvants. *Seminars in Immunology*, **2018**, 39, 4-13	10.7	30
280	Dual-Isotope SPECT/CT Imaging of the Tuberculosis Subunit Vaccine H56/CAF01: Induction of Strong Systemic and Mucosal IgA and T-Cell Responses in Mice Upon Subcutaneous Prime and Intrapulmonary Boost Immunization. *Frontiers in Immunology*, **2018**, 9, 2825	8.4	16
279	C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial. *PLoS ONE*, **2018**, 13, e0204554	3.7	22
278	Concurrent infection with Mycobacterium tuberculosis confers robust protection against secondary infection in macaques. *PLoS Pathogens*, **2018**, 14, e1007305	7.6	42
277	A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo. *Journal of Visualized Experiments*, **2018**,	1.6	2
276	Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial. *Lancet Respiratory Medicine,the*, **2017**, 5, 259-268	35.1	50
275	Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials. *Vaccine*, **2017**, 35, 1652-1661	4.1	33
274	The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge. *Vaccine*, **2017**, 35, 1705-1711	4.1	11
273	Diagnostic Performance of Tuberculosis-Specific IgG Antibody Profiles in Patients with Presumptive Tuberculosis from Two Continents. *Clinical Infectious Diseases*, **2017**, 64, 947-955	11.6	19
272	Broadening CD4 and CD8 T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes. *Journal of Virology*, **2017**, 91,	6.6	10
271	Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis. *Cell Host and Microbe*, **2017**, 21, 695-706.e5	23.4	98

270	Systematic Investigation of the Role of Surfactant Composition and Choice of oil: Design of a Nanoemulsion-Based Adjuvant Inducing Concomitant Humoral and CD4 T-Cell Responses. *Pharmaceutical Research*, **2017**, 34, 1716-1727	4.5	6
269	Introducing the ESAT-6 free IGRA, a companion diagnostic for TB vaccines based on ESAT-6. *Scientific Reports*, **2017**, 7, 45969	4.9	18
268	Intrauterine inoculation of minipigs with Chlamydia trachomatis during diestrus establishes a longer lasting infection compared to vaginal inoculation during estrus. *Microbes and Infection*, **2017**, 19, 334-342	9.3	11
267	Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective Efficacy. *Journal of Immunology*, **2017**, 198, 3494-3506	5.3	37
266	Novel Vaccination Strategies Against Tuberculosis **2017**, 369-387		
265	Seasonal Influenza Split Vaccines Confer Partial Cross-Protection against Heterologous Influenza Virus in Ferrets When Combined with the CAF01 Adjuvant. *Frontiers in Immunology*, **2017**, 8, 1928	8.4	15
264	High Antigen Dose Is Detrimental to Post-Exposure Vaccine Protection against Tuberculosis. *Frontiers in Immunology*, **2017**, 8, 1973	8.4	22
263	Robust antibody and CD8 T-cell responses induced by CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection. *Npj Vaccines*, **2017**, 2,	9.5	22
262	H1:IC31 vaccination is safe and induces long-lived TNF-IL-2CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial. *Vaccine*, **2017**, 35, 132-141	4.1	22
261	Simultaneous Subcutaneous and Intranasal Administration of a CAF01-Adjuvanted Vaccine Elicits Elevated IgA and Protective Th1/Th17 Responses in the Genital Tract. *Frontiers in Immunology*, **2017**, 8, 569	8.4	26
260	Protective Effect of Vaccine Promoted Neutralizing Antibodies against the Intracellular Pathogen. *Frontiers in Immunology*, **2017**, 8, 1652	8.4	24
259	Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes. *PLoS ONE*, **2017**, 12, e0175707	3.7	12
258	A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN- CMI responses protects against a genital infection in minipigs. *Immunology and Cell Biology*, **2016**, 94, 185-95	5	36
257	The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8(+) T-cell responses: The immunological consequences of the biodistribution profile. *Journal of Controlled Release*, **2016**, 239, 107-17	11.7	44
256	Quantitative Protein Profiling of Chlamydia trachomatis Growth Forms Reveals Defense Strategies Against Tryptophan Starvation. *Molecular and Cellular Proteomics*, **2016**, 15, 3540-3550	7.6	12
255	Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens. *Scientific Reports*, **2016**, 6, 19570	4.9	146
254	Host immunity to Mycobacterium tuberculosis and risk of tuberculosis: A longitudinal study among Greenlanders. *Vaccine*, **2016**, 34, 5975-5983	4.1	5
253	Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle Activation of Human Newborn Dendritic Cells Enables Th1 Polarization. *Journal of Immunology*, **2016**, 197, 4413-4424	5.3	45

252	Reprogramming the T Cell Response to Tuberculosis. *Trends in Immunology*, **2016**, 37, 81-83	14.4	14
251	The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons. *Immunity*, **2016**, 44, 597-608	32.3	307
250	Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection. *European Respiratory Journal*, **2016**, 47, 919-28	13.6	35
249	Modulation of Primary Immune Response by Different Vaccine Adjuvants. *Frontiers in Immunology*, **2016**, 7, 427	8.4	46
248	Genital tract lesions in sexually mature G□ttingen minipigs during the initial stages of experimental vaginal infection with Chlamydia trachomatis serovar D. *BMC Veterinary Research*, **2016**, 12, 200	2.7	7
247	Testing the H56 Vaccine Delivered in 4 Different Adjuvants as a BCG-Booster in a Non-Human Primate Model of Tuberculosis. *PLoS ONE*, **2016**, 11, e0161217	3.7	27
246	Identifying protective Streptococcus pyogenes vaccine antigens recognized by both B and T cells in human adults and children. *Scientific Reports*, **2016**, 6, 22030	4.9	6
245	Comparative Systems Analyses Reveal Molecular Signatures of Clinically tested Vaccine Adjuvants. *Scientific Reports*, **2016**, 6, 39097	4.9	36
244	Strategies to enhance immunogenicity of cDNA vaccine encoded antigens by modulation of antigen processing. *Vaccine*, **2016**, 34, 5132-5140	4.1	8
243	TB vaccines; promoting rapid and durable protection in the lung. *Current Opinion in Immunology*, **2015**, 35, 55-62	7.8	24
242	First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. *Vaccine*, **2015**, 33, 4130-40	4.1	120
241	Protein energy malnutrition during vaccination has limited influence on vaccine efficacy but abolishes immunity if administered during Mycobacterium tuberculosis infection. *Infection and Immunity*, **2015**, 83, 2118-26	3.7	22
240	Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach. *Journal of Controlled Release*, **2015**, 210, 48-57	11.7	60
239	Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein. *Journal of Infectious Diseases*, **2015**, 212, 978-89	7	76
238	Differential influence of nutrient-starved Mycobacterium tuberculosis on adaptive immunity results in progressive tuberculosis disease and pathology. *Infection and Immunity*, **2015**, 83, 4731-9	3.7	14
237	Adaptive Immunity against Streptococcus pyogenes in Adults Involves Increased IFN-□and IgG3 Responses Compared with Children. *Journal of Immunology*, **2015**, 195, 1657-64	5.3	31
236	Characterization of the Antigen-Specific CD4(+) T Cell Response Induced by Prime-Boost Strategies with CAF01 and CpG Adjuvants Administered by the Intranasal and Subcutaneous Routes. *Frontiers in Immunology*, **2015**, 6, 430	8.4	24
235	Intramuscular Priming and Intranasal Boosting Induce Strong Genital Immunity Through Secretory IgA in Minipigs Infected with Chlamydia trachomatis. *Frontiers in Immunology*, **2015**, 6, 628	8.4	41

234	Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4+ T Cells. *Vaccine Journal*, **2015**, 22, 688-96		7
233	The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial. *Vaccine*, **2015**, 33, 3592-9	4.1	57
232	Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats. *Vaccine*, **2015**, 33, 1873-9	4.1	13
231	Peptide-specific T helper cells identified by MHC class II tetramers differentiate into several subtypes upon immunization with CAF01 adjuvanted H56 tuberculosis vaccine formulation. *Vaccine*, **2015**, 33, 6823-30	4.1	13
230	Human B cells produce chemokine CXCL10 in the presence of Mycobacterium tuberculosis specific T cells. *Tuberculosis*, **2015**, 95, 40-7	2.6	10
229	Characterization of protective immune responses promoted by human antigen targets in a urogenital Chlamydia trachomatis mouse model. *Vaccine*, **2014**, 32, 685-92	4.1	12
228	Protective CD4 T cells targeting cryptic epitopes of Mycobacterium tuberculosis resist infection-driven terminal differentiation. *Journal of Immunology*, **2014**, 192, 3247-58	5.3	53
227	High-frequency vaccine-induced CD8+ T cells specific for an epitope naturally processed during infection with Mycobacterium tuberculosis do not confer protection. *European Journal of Immunology*, **2014**, 44, 1699-709	6.1	30
226	Tuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 1096-101	11.5	37
225	Tuberculosis vaccines--rethinking the current paradigm. *Trends in Immunology*, **2014**, 35, 387-95	14.4	92
224	Novel vaccination strategies against tuberculosis. *Cold Spring Harbor Perspectives in Medicine*, **2014**, 4,	5.4	103
223	Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant. *Vaccine*, **2014**, 32, 3927-35	4.1	74
222	Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01. *PLoS ONE*, **2014**, 9, e100879	3.7	27
221	A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4+ T-cell response. *Nanomedicine*, **2014**, 9, 2625-38	5.6	12
220	A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. *Vaccine*, **2014**, 32, 7098-107	4.1	152
219	An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines. *Microbial Cell Factories*, **2014**, 13, 162	6.4	30
218	Analysis of protein species differentiation among mycobacterial low-Mr-secreted proteins by narrow pH range Immobiline gel 2-DE-MALDI-MS. *Journal of Proteomics*, **2014**, 97, 235-44	3.9	25
217	Safety and immunogenicity of H1/IC31 , an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial. *PLoS ONE*, **2014**, 9, e114602	3.7	44

216	Assessment of T cell response to novel Mycobacterium tuberculosis synthetic overlapping peptides mixtures (Rv2659 and Rv2660) and ESAT-6 in Egyptian patients. *The Egyptian Journal of Immunology / Egyptian Association of Immunologists*, **2014**, 21, 75-83	0.6	4
215	Development of a proof of concept immunochromatographic lateral flow assay for point of care diagnosis of Mycobacterium tuberculosis. *BMC Research Notes*, **2013**, 6, 202	2.3	6
214	Parasitic infection may be associated with discordant responses to QuantiFERON and tuberculin skin test in apparently healthy children and adolescents in a tuberculosis endemic setting, Ethiopia. *BMC Infectious Diseases*, **2013**, 13, 265	4	16
213	Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells. *Journal of Immunology*, **2013**, 190, 6311-9	5.3	130
212	Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01. *Journal of Controlled Release*, **2013**, 167, 256-64	11.7	32
211	Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in Guinea-Bissau. *AIDS Research and Human Retroviruses*, **2013**, 29, 1504-12	1.6	38
210	Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection. *Clinical Immunology*, **2013**, 146, 120-30	9	32
209	Bettering BCG: a tough task for a TB vaccine?. *Nature Medicine*, **2013**, 19, 410-1	50.5	18
208	The supramolecular structure is decisive for the immunostimulatory properties of synthetic analogues of a mycobacterial lipid in vitro. *RSC Advances*, **2013**, 3, 20673-20683	3.7	14
207	Cell-mediated and humoral immune responses after immunization of calves with a recombinant multiantigenic Mycobacterium avium subsp. paratuberculosis subunit vaccine at different ages. *Vaccine Journal*, **2013**, 20, 551-8		12
206	Proteomic profiling of Mycobacterium tuberculosis identifies nutrient-starvation-responsive toxin-antitoxin systems. *Molecular and Cellular Proteomics*, **2013**, 12, 1180-91	7.6	105
205	Randomised clinical trial investigating the specificity of a novel skin test (C-Tb) for diagnosis of M. tuberculosis infection. *PLoS ONE*, **2013**, 8, e64215	3.7	32
204	Broadening of the T-cell repertoire to HIV-1 Gag p24 by vaccination of HLA-A2/DR transgenic mice with overlapping peptides in the CAF05 adjuvant. *PLoS ONE*, **2013**, 8, e63575	3.7	12
203	Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis model. *PLoS ONE*, **2013**, 8, e72185	3.7	24
202	ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination. *PLoS ONE*, **2013**, 8, e80579	3.7	72
201	Developing solid particulate vaccine adjuvants: surface bound antigen favours a humoural response, whereas entrapped antigen shows a tendency for cell mediated immunity. *Current Drug Delivery*, **2013**, 10, 268-78	3.2	9
200	A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog. *Journal of Controlled Release*, **2012**, 160, 468-76	11.7	78
199	Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset. *Infection and Immunity*, **2012**, 80, 3533-44	3.7	102

198	A structurally informed autotransporter platform for efficient heterologous protein secretion and display. *Microbial Cell Factories*, **2012**, 11, 85	6.4	34
197	Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses. *Journal of Immunology*, **2012**, 188, 4828-37	5.3	61
196	Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein. *PLoS ONE*, **2012**, 7, e46395	3.7	30
195	Deciphering the proteome of the in vivo diagnostic reagent "purified protein derivative" from Mycobacterium tuberculosis. *Proteomics*, **2012**, 12, 979-91	4.8	37
194	Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice. *Infection and Immunity*, **2012**, 80, 1510-8	3.7	53
193	CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice. *Cancer Immunology, Immunotherapy*, **2012**, 61, 893-903	7.4	32
192	The hunt for a global killer. *Human Vaccines and Immunotherapeutics*, **2012**, 8, 547-53	4.4	
191	The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. *Journal of Clinical Investigation*, **2012**, 122, 303-14	15.9	172
190	Immune responses to ESAT-6 and CFP-10 by FASCIA and multiplex technology for diagnosis of M. tuberculosis infection; IP-10 is a promising marker. *PLoS ONE*, **2012**, 7, e43438	3.7	33
189	Cationic liposomes as vaccine adjuvants. *Expert Review of Vaccines*, **2011**, 10, 513-21	5.2	126
188	Liposomal vaccine delivery systems. *Expert Opinion on Drug Delivery*, **2011**, 8, 505-19	8	104
187	Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. *Vaccine*, **2011**, 29, 2100-9	4.1	103
186	Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes. *Vaccine*, **2011**, 29, 6283-91	4.1	45
185	Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. *Vaccine*, **2011**, 29, 7067-74	4.1	51
184	Improved long-term protection against Mycobacterium tuberculosis Beijing/W in mice after intra-dermal inoculation of recombinant BCG expressing latency associated antigens. *Vaccine*, **2011**, 29, 8740-4	4.1	27
183	The Effect of Mycobacterium avium Complex Infections on Routine Mycobacterium bovis Diagnostic Tests. *Veterinary Medicine International*, **2011**, 2011, 145092	1.5	19
182	Validation of the ALS assay in adult patients with culture confirmed pulmonary tuberculosis. *PLoS ONE*, **2011**, 6, e16425	3.7	19
181	A multistage tuberculosis vaccine that confers efficient protection before and after exposure. *Nature Medicine*, **2011**, 17, 189-94	50.5	405

180	Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method. *Journal of Controlled Release*, **2011**, 150, 307-17	11.7	74
179	Detection of proliferative responses to ESAT-6 and CFP-10 by FASCIA assay for diagnosis of Mycobacterium tuberculosis infection. *Journal of Immunological Methods*, **2011**, 370, 55-64	2.5	17
178	Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo. *Pharmaceutical Research*, **2011**, 28, 553-62	4.5	41
177	Subunit vaccines: distearoylphosphatidylcholine-based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium-based cationic liposomes as an adjuvant delivery system. *Journal of Pharmaceutical Sciences*, **2011**, 100, 1856-65	3.9	15
176	Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3Β[N-(NΡ,NΡDimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses. *Molecular Pharmaceutics*, **2011**, 8, 153-61	5.6	80
175	Modulation of cell death by M. tuberculosis as a strategy for pathogen survival. *Clinical and Developmental Immunology*, **2011**, 2011, 678570		36
174	CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets. *PLoS ONE*, **2011**, 6, e22891	3.7	23
173	T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection. *Immunology*, **2010**, 129, 75-86	7.8	71
172	Potential role for ESAT6 in dissemination of M. tuberculosis via human lung epithelial cells. *Molecular Microbiology*, **2010**, 75, 92-106	4.1	82
171	Syringe free vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis. *PLoS ONE*, **2010**, 5, e15043	3.7	14
170	Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. *Journal of Immunology*, **2010**, 184, 2756-60	5.3	357
169	CD4 and CD8 T-cell responses to mycobacterial antigens in African children. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 182, 120-9	10.2	38
168	First in humans: a new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses. *Hum Vaccin*, **2010**, 6, 1007-15		50
167	Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. *Vaccine*, **2010**, 28, 3571-81	4.1	164
166	Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease. *Vaccine*, **2010**, 29, 51-7	4.1	49
165	Expression of apoptosis-related genes in an Ethiopian cohort study correlates with tuberculosis clinical status. *European Journal of Immunology*, **2010**, 40, 291-301	6.1	20
164	Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. *Vaccine*, **2010**, 28, 1084-93	4.1	49
163	CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. *International Journal of Pharmaceutics*, **2010**, 390, 19-24	6.5	44

162	Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. *Journal of Controlled Release*, **2010**, 142, 180-6	11.7	142
161	Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. *Journal of Controlled Release*, **2010**, 145, 102-8	11.7	135
160	Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis. *European Journal of Immunology*, **2010**, 40, 1342-54	6.1	18
159	Protection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model. *PLoS ONE*, **2010**, 5, e10768	3.7	44
158	First-in-man open clinical trial of a combined rdESAT-6 and rCFP-10 tuberculosis specific skin test reagent. *PLoS ONE*, **2010**, 5, e11277	3.7	23
157	Determining adjuvant activity on T-cell function in vivo: Th cells. *Methods in Molecular Biology*, **2010**, 626, 213-29	1.4	3
156	Isolation of Mycobacterium avium subspecies paratuberculosis reactive CD4 T cells from intestinal biopsies of Crohn's disease patients. *PLoS ONE*, **2009**, 4, e5641	3.7	42
155	Distinct differences in the expansion and phenotype of TB10.4 specific CD8 and CD4 T cells after infection with Mycobacterium tuberculosis. *PLoS ONE*, **2009**, 4, e5928	3.7	21
154	Signal regulatory protein alpha (SIRPalpha) cells in the adaptive response to ESAT-6/CFP-10 protein of tuberculous mycobacteria. *PLoS ONE*, **2009**, 4, e6414	3.7	5
153	A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice. *PLoS ONE*, **2009**, 4, e6950	3.7	37
152	Quality and vaccine efficacy of CD4+ T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis. *Journal of Immunology*, **2009**, 183, 2659-68	5.3	73
151	Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. *Journal of Immunology*, **2009**, 182, 8047-55	5.3	313
150	Novel generation mycobacterial adjuvant based on liposome-encapsulated monomycoloyl glycerol from Mycobacterium bovis bacillus Calmette-Guérin. *Journal of Immunology*, **2009**, 183, 2294-302	5.3	33
149	A simple mycobacterial monomycolated glycerol lipid has potent immunostimulatory activity. *Journal of Immunology*, **2009**, 182, 424-32	5.3	43
148	Adjuvants induce distinct immunological phenotypes in a bovine tuberculosis vaccine model. *Vaccine Journal*, **2009**, 16, 1443-8		17
147	Liposome-based cationic adjuvant formulations (CAF): past, present, and future. *Journal of Liposome Research*, **2009**, 19, 2-11	6.1	88
146	A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells. *PLoS ONE*, **2009**, 4, e5771	3.7	76
145	Risk of sensitization in healthy adults following repeated administration of rdESAT-6 skin test reagent by the Mantoux injection technique. *Tuberculosis*, **2009**, 89, 158-62	2.6	8

144	TB vaccines: current status and future perspectives. *Immunology and Cell Biology*, **2009**, 87, 279-86	5	60
143	Adjuvant properties of a simplified C32 monomycolyl glycerol analogue. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 2029-32	2.9	19
142	Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. *Journal of Experimental Medicine*, **2009**, 206, 89-97	16.6	243
141	Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein. *Vaccine*, **2009**, 27, 6894-904	4.1	23
140	Transient facial nerve paralysis (Bell? palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. *PLoS ONE*, **2009**, 4, e6999	3.7	211
139	CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. *PLoS ONE*, **2009**, 4, e5139	3.7	55
138	Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. *PLoS ONE*, **2009**, 4, e5930	3.7	125
137	Immunological memory transferred with CD4 T cells specific for tuberculosis antigens Ag85B-TB10.4: persisting antigen enhances protection. *PLoS ONE*, **2009**, 4, e8272	3.7	14
136	Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection. *Immunology*, **2008**, 124, 175-85	7.8	58
135	Double-blind randomized Phase I study comparing rdESAT-6 to tuberculin as skin test reagent in the diagnosis of tuberculosis infection. *Tuberculosis*, **2008**, 88, 249-61	2.6	41
134	Identification of Rv0222 from RD4 as a novel serodiagnostic target for tuberculosis. *Tuberculosis*, **2008**, 88, 335-43	2.6	28
133	Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. *PLoS ONE*, **2008**, 3, e3116	3.7	216
132	PLGA microspheres for the delivery of a novel subunit TB vaccine. *Journal of Drug Targeting*, **2008**, 16, 282-93	5.4	55
131	NIR transmission spectroscopy for rapid determination of lipid and lyoprotector content in liposomal vaccine adjuvant system CAF01. *European Journal of Pharmaceutics and Biopharmaceutics* , **2008**, 70, 914-20	5.7	18
130	alpha,alphaPtrehalose 6,6Pdibehenate in non-phospholipid-based liposomes enables direct interaction with trehalose, offering stability during freeze-drying. *Biochimica Et Biophysica Acta - Biomembranes*, **2008**, 1778, 1365-73	3.8	35
129	Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres. *Journal of Drug Targeting*, **2008**, 16, 543-54	5.4	25
128	Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. *Journal of Infectious Diseases*, **2008**, 198, 758-67	7	67
127	Primary activation of antigen-specific naive CD4+ and CD8+ T cells following intranasal vaccination with recombinant bacteria. *Infection and Immunity*, **2008**, 76, 5817-25	3.7	34

126	Antigenic profiling of a Chlamydia trachomatis gene-expression library. *Journal of Infectious Diseases*, **2008**, 197, 897-905	7	34
125	Ex vivo cytokine mRNA levels correlate with changing clinical status of ethiopian TB patients and their contacts over time. *PLoS ONE*, **2008**, 3, e1522	3.7	45
124	ESAT-6/CFP10 skin test predicts disease in M. tuberculosis-infected guinea pigs. *PLoS ONE*, **2008**, 3, e1978	3.7	25
123	Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. *Angiogenesis*, **2008**, 11, 381-93	10.6	28
122	Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells. *European Journal of Immunology*, **2008**, 38, 1247-56	6.1	42
121	Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant. *PLoS ONE*, **2008**, 3, e3683	3.7	50
120	Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. *Nature Medicine*, **2007**, 13, 843-50	50.5	1081
119	The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. *Immunology*, **2007**, 121, 216-26	7.8	144
118	Cationic liposomes as vaccine adjuvants. *Expert Review of Vaccines*, **2007**, 6, 785-96	5.2	109
117	PrimaTB STAT-PAK assay, a novel, rapid lateral-flow test for tuberculosis in nonhuman primates. *Vaccine Journal*, **2007**, 14, 1158-64		58
116	Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection. *Journal of Immunology*, **2007**, 178, 3721-30	5.3	49
115	Induction of CD8 T cells against a novel epitope in TB10.4: correlation with mycobacterial virulence and the presence of a functional region of difference-1. *Journal of Immunology*, **2007**, 179, 3973-81	5.3	78
114	Detecting a low prevalence of latent tuberculosis among health care workers in Denmark detected by M. tuberculosis specific IFN-gamma whole-blood test. *Scandinavian Journal of Infectious Diseases*, **2007**, 39, 554-9		46
113	Identification of human T cell targets recognized during Chlamydia trachomatis genital infection. *Journal of Infectious Diseases*, **2007**, 196, 1546-52	7	18
112	Evaluation of Mycobacterium tuberculosis--specific antibody responses in populations with different levels of exposure from Tanzania, Ethiopia, Brazil, and Denmark. *Clinical Infectious Diseases*, **2007**, 45, 575-82	11.6	52
111	The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. *Infection and Immunity*, **2007**, 75, 408-16	3.7	64
110	Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-drying. *Biochimica Et Biophysica Acta - Biomembranes*, **2007**, 1768, 2120-9	3.8	67
109	Vaccine strategies against latent tuberculosis infection. *Trends in Microbiology*, **2007**, 15, 7-13	12.4	90

108	The prognosis of latent tuberculosis: can disease be predicted?. *Trends in Molecular Medicine*, **2007**, 13, 175-82	11.5	152
107	A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice. *Journal of Pharmacy and Pharmacology*, **2006**, 58, 787-99	4.8	62
106	Prospects for a novel vaccine against tuberculosis. *Veterinary Microbiology*, **2006**, 112, 163-9	3.3	31
105	TB vaccine strategies--what is needed to solve a complex problem?. *Tuberculosis*, **2006**, 86, 163-8	2.6	26
104	Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis. *European Journal of Immunology*, **2006**, 36, 3346-55	6.1	62
103	The 6-kilodalton early secreted antigenic target-responsive, asymptomatic contacts of tuberculosis patients express elevated levels of interleukin-4 and reduced levels of gamma interferon. *Infection and Immunity*, **2006**, 74, 2817-22	3.7	34
102	Identification of CT521 as a frequent target of Th1 cells in patients with urogenital Chlamydia trachomatis infection. *Journal of Infectious Diseases*, **2006**, 194, 1258-66	7	21
101	Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. *Vaccine Journal*, **2006**, 13, 179-86		159
100	Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. *Journal of Immunology*, **2006**, 177, 6353-60	5.3	153
99	Tuberculosis in elephants: antibody responses to defined antigens of Mycobacterium tuberculosis, potential for early diagnosis, and monitoring of treatment. *Vaccine Journal*, **2006**, 13, 722-32		102
98	Use of enzyme-linked immunospot assay with Mycobacterium tuberculosis-specific peptides for diagnosis of recent infection with M. tuberculosis after accidental laboratory exposure. *Journal of Clinical Microbiology*, **2006**, 44, 1197-201	9.7	17
97	Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. *Vaccine*, **2006**, 24, 5452-60	4.1	104
96	Novel overlapping coding sequences in Chlamydia trachomatis. *FEMS Microbiology Letters*, **2006**, 265, 106-17	2.9	15
95	Cytokine profiles in tuberculosis patients and healthy subjects in response to complex and single antigens of Mycobacterium tuberculosis. *FEMS Immunology and Medical Microbiology*, **2006**, 47, 254-61		34
94	Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. *Microbes and Infection*, **2006**, 8, 2052-60	9.3	220
93	Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. *Journal of Immunology*, **2005**, 174, 6332-9	5.3	199
92	Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system. *Infection and Immunity*, **2005**, 73, 5817-26	3.7	72
91	Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6Pdibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. *Biochimica Et Biophysica Acta - Biomembranes*, **2005**, 1718, 22-31	3.8	254

90	Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. *Vaccine*, **2005**, 23, 2740-50	4.1	196
89	Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. *Vaccine Journal*, **2005**, 12, 491-6		133
88	The success and failure of BCG - implications for a novel tuberculosis vaccine. *Nature Reviews Microbiology*, **2005**, 3, 656-62	22.2	531
87	Diagnosis of latent Mycobacterium tuberculosis infection: is the demise of the Mantoux test imminent?. *Expert Review of Anti-Infective Therapy*, **2005**, 3, 981-93	5.5	55
86	TB subunit vaccines--putting the pieces together. *Microbes and Infection*, **2005**, 7, 911-21	9.3	47
85	Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA, ELISPOT and quantitative PCR. *Journal of Immunological Methods*, **2005**, 298, 129-41	2.5	47
84	Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. *Tuberculosis*, **2005**, 85, 29-38	2.6	135
83	Vaccines for tuberculosis: novel concepts and recent progress. *Clinical Microbiology Reviews*, **2005**, 18, 687-702	34	85
82	ESAT-6 and CFP-10 in clinical versus environmental isolates of Mycobacterium kansasii. *Journal of Infectious Diseases*, **2005**, 191, 1301-10	7	41
81	Assessing the serodiagnostic potential of 35 Mycobacterium tuberculosis proteins and identification of four novel serological antigens. *Journal of Clinical Microbiology*, **2005**, 43, 57-65	9.7	83
80	Learning from BCG: Designing a better tuberculosis vaccine. *Discovery Medicine*, **2005**, 5, 383-7	2.5	4
79	Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis. *Journal of Infectious Diseases*, **2004**, 190, 2146-53	7	54
78	Mapping immune reactivity toward Rv2653 and Rv2654: two novel low-molecular-mass antigens found specifically in the Mycobacterium tuberculosis complex. *Journal of Infectious Diseases*, **2004**, 189, 812-9	7	53
77	Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. *Infection and Immunity*, **2004**, 72, 6148-50	3.7	167
76	Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 170, 65-9	10.2	258
75	Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection. *Journal of Clinical Microbiology*, **2004**, 42, 2379-87	9.7	105
74	Protein-protein interactions of proteins from the ESAT-6 family of Mycobacterium tuberculosis. *Journal of Bacteriology*, **2004**, 186, 2487-91	3.5	49
73	Association of tuberculin-boosted antibody responses with pathology and cell-mediated immunity in cattle vaccinated with Mycobacterium bovis BCG and infected with M. bovis. *Infection and Immunity*, **2004**, 72, 2462-7	3.7	109

72	Characterization of a Mycobacterium tuberculosis peptide that is recognized by human CD4+ and CD8+ T cells in the context of multiple HLA alleles. *Journal of Immunology*, **2004**, 173, 1966-77	5.3	73
71	Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2. *Journal of Immunology*, **2004**, 172, 6938-43	5.3	149
70	Reactivation of tuberculosis during immunosuppressive treatment in a patient with a positive QuantiFERON-RD1 test. *Scandinavian Journal of Infectious Diseases*, **2004**, 36, 499-501		47
69	CFP10 discriminates between nonacetylated and acetylated ESAT-6 of Mycobacterium tuberculosis by differential interaction. *Proteomics*, **2004**, 4, 2954-60	4.8	73
68	TB diagnosis in non-human primates: comparison of two interferon-gamma assays and the skin test for identification of Mycobacterium tuberculosis infection. *Veterinary Immunology and Immunopathology*, **2004**, 100, 61-71	2	40
67	ESAT-6 proteins: protective antigens and virulence factors?. *Trends in Microbiology*, **2004**, 12, 500-8	12.4	247
66	Genomic approach to identification of Mycobacterium bovis diagnostic antigens in cattle. *Journal of Clinical Microbiology*, **2003**, 41, 3719-28	9.7	45
65	PPE protein (Rv3873) from DNA segment RD1 of Mycobacterium tuberculosis: strong recognition of both specific T-cell epitopes and epitopes conserved within the PPE family. *Infection and Immunity*, **2003**, 71, 6116-23	3.7	100
64	Selecting the components for a safe and efficient tuberculosis subunit vaccine--recent progress and post-genomic insights. *Current Pharmaceutical Biotechnology*, **2003**, 4, 69-83	2.6	7
63	The potential of recombinant antigens ESAT-6, MPT63 and mig for specific discrimination of Mycobacterium tuberculosis and M. avium infection. *European Journal of Pediatrics*, **2003**, 162, 534-536	4.1	13
62	Human T-cell responses to the RD1-encoded protein TB27.4 (Rv3878) from Mycobacterium tuberculosis. *Immunology*, **2003**, 110, 507-12	7.8	18
61	A novel TB vaccine; strategies to combat a complex pathogen. *Immunology Letters*, **2003**, 85, 207-11	4.1	18
60	Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. *Lancet, The*, **2003**, 361, 1168-73	40	481
59	Improved serodetection of Mycobacterium bovis infection in badgers (Meles meles) using multiantigen test formats. *Diagnostic Microbiology and Infectious Disease*, **2003**, 46, 197-203	2.9	79
58	Gamma interferon responses induced by a panel of recombinant and purified mycobacterial antigens in healthy, non-mycobacterium bovis BCG-vaccinated Malawian young adults. *Vaccine Journal*, **2003**, 10, 602-11		32
57	Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. *Journal of Bacteriology*, **2002**, 184, 3485-91	3.5	157
56	Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. *Infection and Immunity*, **2002**, 70, 5446-53	3.7	134
55	Responses of bovine WC1(+) gammadelta T cells to protein and nonprotein antigens of Mycobacterium bovis. *Infection and Immunity*, **2002**, 70, 6114-20	3.7	53

54	Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. *Journal of Clinical Microbiology*, **2002**, 40, 704-6	9.7	189
53	Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. *Infection and Immunity*, **2002**, 70, 3111-21	3.7	90
52	Tuberculosis vaccine development. *Current Opinion in Pulmonary Medicine*, **2002**, 8, 183-7	3	25
51	Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. *Infection and Immunity*, **2002**, 70, 672-8	3.7	343
50	Interleukin-6 regulates the phenotype of the immune response to a tuberculosis subunit vaccine. *Immunology*, **2001**, 103, 375-81	7.8	20
49	Failure to induce enhanced protection against tuberculosis by increasing T-cell-dependent interferon-gamma generation. *Immunology*, **2001**, 104, 157-61	7.8	58
48	Use of ESAT-6 in the interferon-gamma test for diagnosis of bovine tuberculosis following skin testing. *Veterinary Microbiology*, **2001**, 80, 37-46	3.3	69
47	Tuberculin skin testing compared with T-cell responses to Mycobacterium tuberculosis-specific and nonspecific antigens for detection of latent infection in persons with recent tuberculosis contact. *Vaccine Journal*, **2001**, 8, 1089-96		59
46	Antigen Discovery and Tuberculosis Vaccine Development in the Post-genomic Era. *Scandinavian Journal of Infectious Diseases*, **2001**, 33, 79-83		3
45	Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. *Infection and Immunity*, **2001**, 69, 2773-8	3.7	287
44	Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community controls in The Gambia. *Infection and Immunity*, **2001**, 69, 6554-7	3.7	87
43	Use of ESAT-6 and CFP-10 antigens for diagnosis of extrapulmonary tuberculosis. *Journal of Infectious Diseases*, **2001**, 183, 175-6	7	66
42	Preparation of Culture Filtrate Proteins from Mycobacterium tuberculosis. *Methods in Molecular Medicine*, **2001**, 54, 205-15		6
41	Long-lived immune response to early secretory antigenic target 6 in individuals who had recovered from tuberculosis. *Clinical Infectious Diseases*, **2001**, 33, 1336-40	11.6	51
40	Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA. *Vaccine*, **2001**, 19, 4028-35	4.1	61
39	TB vaccines: progress and problems. *Trends in Immunology*, **2001**, 22, 160-8	14.4	124
38	Tuberculosis vaccines: developmental work and the future. *Current Opinion in Pulmonary Medicine*, **2000**, 6, 203-8	3	7
37	Mapping and identification of Mycobacterium tuberculosis proteins by two-dimensional gel electrophoresis, microsequencing and immunodetection. *Electrophoresis*, **2000**, 21, 935-48	3.6	152

36	Towards the proteome of Mycobacterium tuberculosis. *Electrophoresis*, **2000**, 21, 3740-56	3.6	141
35	Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. *European Journal of Immunology*, **2000**, 30, 1724-32	6.1	140
34	Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. *European Journal of Immunology*, **2000**, 30, 3689-98	6.1	284
33	Vaccinia expression of Mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85. *Microbes and Infection*, **2000**, 2, 1677-85	9.3	24
32	Detection of active tuberculosis infection by T cell responses to early-secreted antigenic target 6-kDa protein and culture filtrate protein 10. *Journal of Infectious Diseases*, **2000**, 181, 1850-4	7	159
31	CD4(+) T-cell subsets that mediate immunological memory to Mycobacterium tuberculosis infection in mice. *Infection and Immunity*, **2000**, 68, 621-9	3.7	84
30	ESAT-6 subunit vaccination against Mycobacterium tuberculosis. *Infection and Immunity*, **2000**, 68, 791-5	3.7	291
29	Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. *Infection and Immunity*, **2000**, 68, 214-20	3.7	240
28	Antigenic equivalence of human T-cell responses to Mycobacterium tuberculosis-specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides. *Infection and Immunity*, **2000**, 68, 3314-21	3.7	158
27	Human CD8(+) T cells specific for Mycobacterium tuberculosis secreted antigens in tuberculosis patients and healthy BCG-vaccinated controls in The Gambia. *Infection and Immunity*, **2000**, 68, 7144-8	3.7	61
26	Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10. *Vaccine Journal*, **2000**, 7, 155-60		256
25	Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells **2000**, 30, 3689		7
24	Towards the proteome of Mycobacterium tuberculosis **2000**, 21, 3740		4
23	Immunological evaluation of novel Mycobacterium tuberculosis culture filtrate proteins. *FEMS Immunology and Medical Microbiology*, **1999**, 23, 159-64		29
22	Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. *Journal of Infectious Diseases*, **1999**, 179, 637-45	7	257
21	Differentiation between Mycobacterium bovis BCG-vaccinated and M. bovis-infected cattle by using recombinant mycobacterial antigens. *Vaccine Journal*, **1999**, 6, 1-5		117
20	Cellular immune responses to ESAT-6 discriminate between patients with pulmonary disease due to Mycobacterium avium complex and those with pulmonary disease due to Mycobacterium tuberculosis. *Vaccine Journal*, **1999**, 6, 606-9		61
19	Differential T-cell recognition of native and recombinant Mycobacterium tuberculosis GroES. *Infection and Immunity*, **1999**, 67, 5552-8	3.7	20

18	Interleukin-6 and interleukin-12 participate in induction of a type 1 protective T-cell response during vaccination with a tuberculosis subunit vaccine. *Infection and Immunity*, **1999**, 67, 5747-54	3.7	88
17	T-cell recognition of Mycobacterium tuberculosis culture filtrate fractions in tuberculosis patients and their household contacts. *Infection and Immunity*, **1999**, 67, 5967-71	3.7	54
16	A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). *Microbiology (United Kingdom)*, **1998**, 144 (Pt 11), 3195-3203	2.9	388
15	B-cell epitopes and quantification of the ESAT-6 protein of Mycobacterium tuberculosis. *Infection and Immunity*, **1998**, 66, 717-23	3.7	80
14	Identification and characterization of a 29-kilodalton protein from Mycobacterium tuberculosis culture filtrate recognized by mouse memory effector cells. *Infection and Immunity*, **1998**, 66, 2728-35	3.7	59
13	Delayed-type hypersensitivity responses to ESAT-6 and MPT64 from Mycobacterium tuberculosis in the guinea pig. *Infection and Immunity*, **1998**, 66, 3454-6	3.7	85
12	Two-dimensional electrophoresis for analysis of Mycobacterium tuberculosis culture filtrate and purification and characterization of six novel proteins. *Infection and Immunity*, **1998**, 66, 3492-500	3.7	113
11	The potential of the ESAT-6 antigen secreted by virulent mycobacteria for specific diagnosis of tuberculosis. *Journal of Infectious Diseases*, **1997**, 175, 1251-4	7	152
10	Immunological requirements for a subunit vaccine against tuberculosis. *Immunology and Cell Biology*, **1997**, 75, 595-603	5	20
9	The T cell response to secreted antigens of Mycobacterium tuberculosis. *Immunobiology*, **1994**, 191, 537-47	3.4	66
8	Simultaneous electroelution of whole SDS-polyacrylamide gels for the direct cellular analysis of complex protein mixtures. *Journal of Immunological Methods*, **1993**, 161, 29-39	2.5	57
7	T cell response to Mycobacterium tuberculosis. *Journal of Infectious Diseases*, **1993**, 167, 1481-97	7	364
6	Proliferative responses to purified and fractionated Bordetella pertussis antigens in mice immunized with whole-cell pertussis vaccine. *Vaccine*, **1993**, 11, 463-72	4.1	9
5	CFP10 discriminates between nonacetylated and acetylated ESAT-6 of Mycobacterium tuberculosis by differential interaction141-152		
4	ESAT-6 and the Mycobacterial ESX Secretion Systems211-222		
3	Immune Intervention Strategies against Tuberculosis571-586		
2	A novel Mycobacterium tuberculosis-specific subunit vaccine provides synergistic immunity upon co-administration with Bacillus Calmette-Guﬁn		1
1	Liposomes in Adjuvant Systems for Parenteral Delivery of Vaccines357-376		4